EO2002 / Emmetrope Ophthalmics - LARVOL DELTA

Study to Assess Safety and Tolerability of Multiple Doses of EO2002 (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Asociación para Evitar la Ceguera en México | Trial primary completion date: Jul 2025 ➔ Dec 2025

Trial primary completion date • Ophthalmology

Safety and Tolerability of EO2002 (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Asociación para Evitar la Ceguera en México | Trial completion date: Dec 2025 ➔ Oct 2026 | Trial primary completion date: Jul 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • Cataract • Ophthalmology

AI Algorithm Aids Morphological Validation in Cell Therapy Products (ARVO 2025) - "Conclusions The AI-based algorithm demonstrated robust detection of fibroblastic changes in Ripasudil-treated EO2002 cells. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Ophthalmology

Disease Modifying Effect of Non-Surgical Cell Therapy for Corneal Edema (ARVO 2025) - "Purpose This study aimed to evaluate the changes in guttae in patients with diagnosis of Fuchs endothelial dystrophy that participated in a non-surgical clinical trial for magnetic corneal endothelial cell therapy (EO2002) at an academic center...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Ophthalmology

Non-Surgical Cell Therapy for Corneal Edema (ARVO 2025) - "Purpose This study aimed to evaluate the safety and efficacy of magnetic human corneal endothelial cells (EO2002) for treating symptomatic corneal edema caused by endothelial dysfunction...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Ophthalmology

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema (clinicaltrials.gov) - P1 | N=42 | Completed | Sponsor: Emmecell | Active, not recruiting ➔ Completed

Trial completion • Ophthalmology

Phase 1 Multicenter Study of Endothelial Magnetic Cell Therapy for Corneal Edema (AAO 2024) - "Conclusion EO2002 is well tolerated, and this novel, nonsurgical approach can be done in the clinic. Data analysis of the last enrolled subjects is ongoing."

Clinical • P1 data • Ophthalmology

Study to Assess Safety and Tolerability of EO2002 (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Asociación para Evitar la Ceguera en México | Trial completion date: Jun 2024 ➔ Dec 2025 | Trial primary completion date: Nov 2023 ➔ Jul 2025

Surgery • Trial completion date • Trial primary completion date • Cataract • Ophthalmology

Study to Assess Safety and Tolerability of Multiple Doses of EO2002 (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Asociación para Evitar la Ceguera en México | Trial completion date: Mar 2024 ➔ Dec 2025 | Trial primary completion date: Sep 2023 ➔ Jul 2025

Trial completion date • Trial primary completion date • Ophthalmology

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema (clinicaltrials.gov) - P1 | N=42 | Active, not recruiting | Sponsor: Emmecell | Recruiting ➔ Active, not recruiting

Enrollment closed • Ophthalmology

A Phase 1, Multicenter Study of Magnetic Human Endothelial Cell Therapy for Corneal Edema (ARVO 2024) - "EO2002 injection is well-tolerated with no significant adverse events or changes in intraocular pressure. This novel, non-surgical treatment approach can be performed in the clinic on subjects with symptomatic corneal.Future results from the remaining portions of the study should offer important details on secondary endpoints in this patient population and valuable information about the safety of all dosages. Further development is ongoing."

Clinical • P1 data • Ophthalmology

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Emmecell | Trial completion date: Dec 2023 ➔ Oct 2024 | Trial primary completion date: Dec 2023 ➔ Oct 2024

Trial completion date • Trial primary completion date • Ophthalmology

Phase 1 Multicenter Study of Endothelial Magnetic Cell Therapy for Corneal Edema (AAO 2023) - "Conclusion EO2002 is well tolerated, and this novel nonsurgical approach can be done in the clinic. Further development is ongoing in the United States."

Clinical • P1 data • Ophthalmology

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Emmecell | N=21 ➔ 42 | Trial completion date: Jun 2023 ➔ Dec 2023 | Trial primary completion date: Jun 2023 ➔ Dec 2023

Enrollment change • Trial completion date • Trial primary completion date • Ophthalmology

Endothelial Magnetic Cell Therapy for Corneal Edema (ASCRS-ASOA 2023) - "Purpose To assess the safety and tolerability of Endothelial Magnetic Cell Injection (EMCI) in subjects with symptomatic corneal edema.MethodsHuman corneal endothelial cells expanded in vitro from a single donor cornea were loaded with magnetic nanoparticles in a cGMP manufacturing setting to produce EO2002.The safety and tolerability of a single intracameral injection of EO2002 with and without endothelial brushing or Descemet stripping was evaluated in a Phase 1, dose-escalating multicenter trial.Up to 21 subjects were enrolled in 7 cohorts to receive EO2002 injection followed by the application of an external magnetic eye patch.Four doses (50K, 150K, 500K and 1M cells) were tested and subjects were followed for 6 months.Outcome measures included safety, decreased corneal thickness and best-corrected visual acuity (BCVA).ResultsStudy is ongoing in the US.To date, 21 subjects with symptomatic corneal edema and BCVA <20/40 have been enrolled and treated with EO2002.No..."

Inflammation

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: Emmecell | Trial primary completion date: Dec 2022 ➔ Jun 2023

Trial primary completion date • Ophthalmology

Study to Assess Safety and Tolerability of Multiple Doses of EO2002 (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Asociación para Evitar la Ceguera en México

New P1 trial • Ophthalmology

Study to Assess Safety and Tolerability of EO2002 (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Asociación para Evitar la Ceguera en México

New P1 trial • Cataract • Ophthalmology